Biotech Values

[mcbio]

I'm not familiar with AVNR at all but it seems to me that a decent number of the more regarded posters on this board would have concluded that this company was a sham based on this NYT article.

AVNR is definitely not a sham. In their prior days (when known as Lidak), they developed Abreva (known as Lidakol originally) for oral herpes and that's now on the market OTC, although they monetized all of their royalty rights I believe.

I'm surprised, given that the condition doesn't even have a proper name and the drug appears to have safety issues, that the FDA approved it.

Count me as surprised as well. When it was noted that there were a higher number of deaths in the Neudexta arm, I thought for sure the drug would be rejected. This just goes to show the unpredictability of FDA decisions and it's why I almost always try to avoid them (and Phase 3 results).